3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
NET
1
Lymphoid
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Endocrine
1
Dermatologic
1
CNS
1
Breast
1
Conditions
Sarcoma
2
Pancreatic Neoplasms
2
Ovarian Neoplasms
2
Breast Neoplasms
2
Thyroid Cancer, Papillary
1
Salivary Gland Neoplasms
1
Prostatic Neoplasms
1
Neuroendocrine Tumors
1
Melanoma
1
Lymphoma, Large-Cell, Anaplastic
1
Head and Neck Neoplasms
1
Colorectal Neoplasms
1
Cholangiocarcinoma
1
Carcinoma, Renal Cell
1
Carcinoma, Non-Small-Cell Lung
1
Brain Neoplasms
1
Interventions
pembrolizumab
41
Nivolumab
18
atezolizumab
8
Specimen Handling
7
Docetaxel
7
durvalumab
6
Paclitaxel
6
Magnetic Resonance Spectroscopy
6
Ipilimumab
6
Cyclophosphamide
6
Carboplatin
6
fludarabine
4
avelumab
4
Oxaliplatin
4
Leucovorin
4
Early Intervention, Educational
4
Counseling
4
Biopsy
4
temsirolimus
3
spartalizumab
3
pazopanib
3
olaparib
3
lenvatinib
3
cabozantinib
3
aldesleukin
3
Trastuzumab
3
Taxes
3
Sirolimus
3
Psychiatric Rehabilitation
3
Fluorouracil
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Carcinoma, Renal Cell
×
entrectinib
×
Gynecologic
×
Clear all
NCT02568267
2026-05-27
STARTRK-2
Hoffmann-La Roche
Phase 2
Active not recruiting
534 enrolled
1 FDA